Specifically, ~85% of radiopharmaceuticals can be detected in clinical practice by SPECT imaging.110 Tumor-specific biological compounds, such as antibodies or peptides, can be used for radiolabeling to produce tumor-targeted SPECT radiopharmaceuticals, e.g., 123I-VEGF for VEGFR targeting, 111In-bevacizumab for VEGF targeting, 111In-trastuzumab for HER2 targeting, and 111In-EGF for EGFR targeting.111–113 These approaches have been explored for monitoring the responses to anticancer treatment in humans.110,111. Here, KDR is linked to neoplasm.